Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased...
Brain
Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a...
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),...
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming...
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage...
Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection
CLEVELAND, March 25, 2025 /PRNewswire/ -- Belay Diagnostics announces its partnership with GenomOncology (GO), a precision medicine software company that provides...
Linus Health to Present New Research Findings at Leading Alzheimer’s and Parkinson’s Conference
AD/PD™ 2025 to feature presentations on Linus Health's digital cognitive health assessments, plus attendees can learn more about company's recent...
DeepIntent Unveils DeepIntent Cortex™, Ushering in the Next Generation of Healthcare Demand Side Platforms
NEW YORK, March 25, 2025 /PRNewswire/ -- DeepIntent, the leading healthcare advertising technology company, today introduced DeepIntent Cortex, its most...
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
Helicore’s first-in-human study is designed to evaluate the safety and tolerability of HCR-188 in a single and multiple ascending dose...
NervGen Pharma to Host Virtual Investor Event
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical...
Epilepsy Foundation of America Harnesses the “Power in Purple” for Special Awareness Day
Purple Day® encourages education, support, and advocacy for the epilepsy communityBOWIE, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Join the Epilepsy...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with...
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a...
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039,...
Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120
Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research FREMONT, Calif., March 24, 2025...
Avatar Medical Receives 510k Clearance for brAIn™ SPS brAIn™ SPS (Shoulder Positioning System) is to be Exclusively Utilized by FX Shoulder Solutions
ADDISON, Texas, March 24, 2025 /PRNewswire/ -- brAIn™ SPS was developed through a collaboration between Avatar Medical and FX Shoulder...
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...